Immunome Ownership | Who Owns Immunome?


OverviewForecastRevenueFinancialsChart

Immunome Ownership Summary


Immunome is owned by 49.36% institutional investors, 7.85% insiders, and 42.79% retail investors. Blackrock is the largest institutional shareholder, holding 36.46% of IMNM shares. Fidelity Growth Compy Commingled Pl S is the top mutual fund, with 5.58% of its assets in Immunome shares.

IMNM Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockImmunome49.36%7.85%42.79%
SectorHealthcare Stocks 231.98%10.74%-142.72%
IndustryBiotech Stocks 381.47%10.55%-292.02%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock3.76M36.46%$45.48M
Fmr13.06M15.01%$152.89M
T. rowe price investment management8.42M9.67%$98.58M
Blackrock funding, inc. /de7.59M8.63%$163.14M
Vanguard group6.04M6.87%$129.71M
Redmile group5.02M5.77%$58.82M
Janus henderson group3.46M5.74%$36.73M
Point72 asset management4.82M5.54%$56.49M
Enavate sciences gp4.77M5.48%$55.84M
Primecap management co/ca/4.69M5.33%$100.64M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Enavate sciences gp4.77M17.05%$55.84M
Redmile group5.02M5.72%$58.82M
Opaleye management3.19M5.27%$37.30M
Pivotal bioventure partners investment advisor502.51K3.40%$5.88M
Silverarc capital management1.13M3.36%$24.19M
Monashee investment management274.86K3.33%$5.90M
Ecor1 capital4.08M2.29%$47.77M
Nan fung trinity (hk)714.55K1.22%$15.35M
Birchview capital, lp105.00K0.93%$1.23M
Readystate asset management lp1.32M0.66%$15.44M

Top Buyers

HolderShares% AssetsChange
Fmr13.06M0.01%6.89M
Blackrock3.76M0.00%2.93M
Jpmorgan chase2.86M0.00%2.82M
Blackrock funding, inc. /de7.59M0.00%1.77M
Primecap management co/ca/4.69M0.08%1.67M

Top Sellers

HolderShares% AssetsChange
Toronto dominion bank1.04M0.02%-1.05M
Vestal point capital, lp---1.00M
Avidity partners management lp---873.89K
Brown advisory---860.78K
Adage capital partners gp---775.00K

New Positions

HolderShares% AssetsChangeValue
Silverarc capital management1.13M3.36%1.13M$24.19M
Pivotal bioventure partners investment advisor502.51K3.40%502.51K$5.88M
Parkman healthcare partners351.13K0.43%351.13K$4.11M
Monashee investment management274.86K3.33%274.86K$5.90M
Axa investment managers180.06K0.01%180.06K$2.11M

Sold Out

HolderChange
National bank of canada /fi/-1.00
Eversource wealth advisors-8.00
Us bancorp \de\-21.00
Lindbrook capital-38.00
Stephens consulting-50.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2025109-33.54%43,416,568-52.49%490.45%67-27.96%23-37.84%
Sep 30, 20251608.11%91,368,86815.03%1051.26%917.06%37-
Jun 30, 20251480.68%79,432,0189.01%911.08%85-20.56%37105.56%
Mar 31, 202514718.55%76,924,34244.29%961.24%10854.29%17-51.43%
Dec 31, 20241231.65%53,309,2873.16%881.20%694.55%3525.00%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Fidelity Growth Compy Commingled Pl S6.16M5.58%693.09K
T. Rowe Price US Small-Cap Core Equity5.13M4.65%2.01M
T. Rowe Price Small-Cap Stock5.13M4.65%220.26K
Fidelity Growth Company Fund4.42M4.01%475.95K
PRIMECAP Odyssey Aggressive Growth3.81M3.46%1.14M
Fidelity Growth Compy Commingled Pl O1.79M2.97%-
Vanguard Total Stock Mkt Idx Inv3.14M2.84%10.48K
T. Rowe Price Instl Small-Cap Stock2.78M2.52%147.91K
T. Rowe Price U.S. SC Core Eq Tr-D2.36M2.14%914.28K
iShares Russell 2000 ETF2.25M2.04%2.25M

Recent Insider Transactions


DateNameRoleActivityValue
Dec 30, 2025SIEGALL CLAY B President and CEOBuy$100.02K
Dec 22, 2025Barchas Isaac-Sell$251.35K
Dec 22, 2025Barchas Isaac-Sell$8.08M
Dec 19, 2025SIEGALL CLAY B President and CEOBuy$149.05K
Dec 19, 2025Tsai Philip Chief Technical OfficerBuy$204.90K

Insider Transactions Trends


DateBuySell
2025 Q442
2025 Q3--
2025 Q21-
2025 Q15-
2024 Q44-

IMNM Ownership FAQ


Who Owns Immunome?

Immunome shareholders are primarily institutional investors at 49.36%, followed by 7.85% insiders and 42.79% retail investors. The average institutional ownership in Immunome's industry, Biotech Stocks , is 381.47%, which Immunome falls below.

Who owns the most shares of Immunome?

Immunome’s largest shareholders are Blackrock (3.76M shares, 36.46%), Fmr (13.06M shares, 15.01%), and T. rowe price investment management (8.42M shares, 9.67%). Together, they hold 61.14% of Immunome’s total shares outstanding.

Does Blackrock own Immunome?

Yes, BlackRock owns 36.46% of Immunome, totaling 3.76M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 45.48M$. In the last quarter, BlackRock increased its holdings by 2.93M shares, a 353.41% change.

Who is Immunome’s biggest shareholder by percentage of total assets invested?

Enavate sciences gp is Immunome’s biggest shareholder by percentage of total assets invested, with 17.05% of its assets in 4.77M Immunome shares, valued at 55.84M$.

Who is the top mutual fund holder of Immunome shares?

Fidelity Growth Compy Commingled Pl S is the top mutual fund holder of Immunome shares, with 5.58% of its total shares outstanding invested in 6.16M Immunome shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools